Genetic diagnosis of subfertility: the impact of meiosis and maternal effects

Alexander Gheldof, Deborah J G Mackay, Ying Cheong, Willem Verpoest

ABSTRACT
During reproductive age, approximately one in seven couples are confronted with fertility problems. While the aetiology is diverse, including infections, metabolic diseases, hormonal imbalances and iatrogenic effects, it is becoming increasingly clear that genetic factors have a significant contribution. Due to the complex nature of infertility that often hints at a multifactorial cause, the search for potentially causal gene mutations in idiopathic infertile couples has remained difficult. Idiopathic infertility patients with a suspicion of an underlying genetic cause can be expected to have mutations in genes that do not readily affect general health but are only essential in certain processes connected to fertility. In this review, we specifically focus on genes involved in meiosis and maternal-effect processes, which are of critical importance for reproduction and initial embryonic development. We give an overview of genes that have already been linked to infertility in human, as well as good candidates which have been described in other organisms. Finally, we propose a phenotypic range in which we expect an optimal diagnostic yield of a meiotic/maternal-effect gene panel.

BACKGROUND
It is estimated that 10%–15% of couples are affected by infertility during reproductive age, with equal distribution of subfertility between men and women.1 A significant proportion of couples are unsuccessful despite having healthy reproductive age, no detectable physical, endocrine or immune problems, apparently adequate quantity and quality of gametes and no apparent technical laboratory issues affecting the Artificial Reproduction Technologies (ART) procedures. For example, 50%–80% of cases diagnosed with primary ovarian insufficiency (POI) remain idiopathic2 3; likewise, in 80% of men with non-obstructive azoospermia, the cause remains unknown.4 For such individuals, there are currently limited options for intervention to optimise fertility. When confronted with idiopathic infertility patients, an important first test that is often used by fertility centres is karyotyping.

MEIOSIS
Meiosis is an essential process of gamete formation, and its genetic disruptions are likely to have a considerable impact on fertility. Expression of meiosis genes is implicated in considerations including ovarian reserve, ovarian response, and oocyte maturation and activation. Meiosis gene mutations may therefore lead to a number of clinical pathologies such as POI, insufficient oocyte maturation and low fertilisation rate.

Several distinct steps are necessary for meiotic completion, including the formation of double-strand breaks (DSBs), chromosome synopsis, homologous recombination (HR), separation of homologous chromosomes during first meiotic...
division (MI) and separation of sister chromatids during meiosis II (MII). Since the spatiotemporal regulation of meiosis is also dependent on somatic cells in humans, namely the granulosa cells in women and Sertoli cells in men, genes involved in the crosstalk between the somatic and the germline compartment are also relevant to meiotic success.

Below, we describe the molecular subprocesses of meiosis and as such define a collection of genes warranting inclusion in a diagnostic gene panel for idiopathic infertility. This will comprise both genes that have already been described in an idiopathic fertility setting, as well as unreported genes that have a high potential to lead to meiotic errors when disturbed (figure 1).

**The synaptonemal complex (SC): basis for chromosome pairing, synopsis and recombination**

An essential premise for meiosis to take place is the correct alignment of homologous chromosomes (pairing) during its initial stages. A crucial mediator for this process is the SC, a multiprotein structure that is assembled during meiotic prophase I and that is essential for synopsis, meiotic crossover and correct segregation of homologous chromosomes during anaphase in the first meiotic division. Given the pivotal role of the SC in meiosis, mutations in SC would be expected to give rise to fertility problems.

The SYCP3 protein is, together with SYCP2, one of the main components of the lateral elements of the SC and is essential for chromosome loading on the SC. Mutations in SYCP3 have been shown in men with non-obstructive azoospermia. Examination of testicular biopsies revealed that the most mature spermatogenic cells were early spermatocytes, indicating a meiotic arrest, whereas SYCP3 mutations in women do not seem to lead to a meiotic arrest but result in recurrent pregnancy loss, probably due to the presence of aneuploidies. This sexual dimorphism is speculated to arise from greater stringency of the pachytene checkpoint in men than in women. To date, no mutations have been found in SYCP2, but mouse Sycp2 mutants show a phenotype reminiscent of human SYCP3 mutations, including the sexual dimorphism. Females lacking the SYCP2-like gene product SYC2PL undergo accelerated reproductive ageing.

Mutations in the SC component SYCE1 have been reported in cases of human infertility. SYCE1 is a component of the central element of the SC. Both male and female Syce1-mutant mice are infertile and are characterised by an arrest in prophase I. Reports of human SYCE1 variants identify azoospermia in affected men and women affected by premature ovarian insufficiency (POI). Additionally, in mice, the absence of Meiob and Spata22, two proteins associating with the SC and forming discrete foci on meiotic chromosomes causes failure of meiotic synopsis. Although Meiob ablation is associated with both male and female infertility in mice, in humans MEIOB mutation has been associated only with male azoospermia. Murine ablation of Spata22 is also associated with male and female infertility through failure of synopsis.

---

**Figure 1** Overview of critical processes during the MI stage. (A) After DNA replication, sister chromatids of both homologous chromosome pairs are held together by multiple units of the cohesion complex. (B) Alignment of the homologous chromosomes is facilitated by the synaptonemal complex. (C) The first step of homologous recombination occurs through the formation of double strand breaks (DSB). This process is Spo-11 dependent, and strand invasion is mediated by the Rad51-DMC1 complex, which is stabilised by Hop2-Mnd1. (D) After homologous recombination, the cohesion complex of the sister chromatids is cleaved by separase along the length of the sister chromatids. Cohesin at the centromeres is protected by shugosin, inhibiting the separase-mediated cleaving. (E) Sister kinetochores connect to microtubules emanating from the same spindle poles, as such separating the newly recombined homologues.
Double strand break formation

Precise alignment of the homologous chromosomes allows the initiation of the next meiotic process, recombination or crossing over (figure 1). Crossover occurs at one or multiple sites along the length of each chromosomal arms, resulting in the formation of chiasmata, and these chiasmata are essential to maintain chromosome cohesion during meiosis. Reduced recombination or incorrect placement of chiasmata is associated with increased incidence of aneuploidy.23–25 Paucity of chiasmata is most likely to lead to aneuploidy in the smallest chromosomes, for example, chromosome 21, there is evidence that the genome-wide frequency of crossover may have some genetic basis. In families where one offspring has Trisomy 21, genome-wide analysis indicates that the frequency of crossovers is reduced in the individual affected by Trisomy 21 and in siblings26; and this crossover frequency may be partly accounted for by variation in the recombination factor PRDM9.27

Interestingly, the helicase-homologous protein HFM1, expressed in male and female germ tissues, appears to be required for formation or resolution of crossovers; in mice lacking this gene product, early steps in crossover are normal, but then most crossovers are eliminated and the majority of germ cells undergo apoptosis.28 Human HFM1 variants have been identified in women affected by POI.29 Furthermore, MCM8 and MCM9, two essential proteins required for HR driven DNA repair, are more widely expressed in somatic tissues, and their ablation results in accumulation of DNA damage in response to replication stress, but nonetheless, the key phenotype of mice lacking these proteins is infertility, apparently due to errors in homologous recombination (HR).30 Variants in MCM8 have been identified in women affected by POI.31 32

Meiotic crossover requires the creation of DSBs in individual chromosomes and subsequent recombination between chromosome homologues. Meiotic DSB generation requires the highly conserved SPO11 topoisomerase-like protein (figure 1). In human, heterozygous SPO11 mutations have been shown in men with azospermia.33 In mouse models entirely lacking Spo11, spermatogenesis arrested before the pachytene stage,34 35 Spo11, spermatogenesis arrested before the pachytene stage,34 35 while oocytes arrested in prophase I.34 35 Spo11, spermatogenesis arrested before the pachytene stage,34 35 while oocytes arrested in prophase I.34 35 Genetic defects in the regulatory machinery of SPO11 could also contribute to a fertility phenotype. Studies in yeast have delineated distinct mechanisms for SPO11 regulation in meiosis, either through intrinsic control of SPO11 dimerisation and nuclear retention, or through regulation of its interaction with DNA recombination hotspots. For instance, Rec102, Rec104 and Ski8 are required for SPO11 dimerisation, DNA binding and nuclear retention in yeast.39–41 However, the SPO11 accessory proteins REC11, Mer2 and Mei4 form a complex that is essential for the DNA binding and guiding of SPO11 to DSB cleavage sites.42 Mei4+/− male mice are unable to initiate DSB formation in meiosis, resulting in synaptic defects and arrest of spermatogenesis.43 Mutations in homologous SPO11-associated genes have however not yet been described in humans.

In mice, an additional factor that has been shown to be necessary for DSB formation/maintenance is Hormad1. Knockout mice meiocytes show a strong reduction in single-stranded DSB ends, as is evidenced by the diminished presence of Dmc1/Rad51 foci.43 As both Hormad1 and its close parologue Hormad2 associate with the axis of unsynapsed chromosomes and have been hypothesised as inhibitors of interstrand DNA repair, thus favourising interhomologous driven repair, chromosome synopsis is disrupted as well in the Hormad1/2−/− models.44 45 On synopsis, Hormad1/2 dissociate from the chromosomal axis, a process that is facilitated by Trip13. Trip13−/− mice oocytes show full chromosome synopsis but are unable to repair the Spo11-mediated DSBs, further supporting the role of Hormad1/2 in interhomologous repair.46 Failure of DSB repair leads to Chk2-dependent oocyte clearance. Interestingly, while testes of Hormad1−/− mice show progressive atrophy, ovarian development does not seem to be affected.47 However, embryos of Hormad1−/− females do not proceed further than the blastocyst stage.

Homologous recombination (HR)

Creation of meiotic DSB is followed by HR, which is driven by cellular DNA repair machinery that is shared between germ-line and somatic cells (figure 1). DSB repair is initiated by the Mre11-Rad50-Nbs1 complex, which attracts both the ataxia telangiectasia mutated (ATM) and ataxia telangiectasia mutated and Rad3 related (ATR) kinases to the DSB sites and which in their turn phosphorylate histone H2AFX that acts as a beacon to attract novel repair associated proteins.48 In addition, ATM phosphorylates multiple DNA damage repair associated factors including CHK2, BRCA1/2 and P53, which subsequently orchestrate crucial cell cycle checkpoints and the potential decision to drive the cell towards apoptosis if DSB repair is unsuccessful.49 Repair by HR is mediated by DMC1 and RAD51 proteins, which form a nucleosome complex around the single strand overhangs of DSBs. RAD51 is an essential facilitator for DMC1-mediated interhomologous strand invasion.50 Interaction of the DMC1/RAD51 complex with the strand invasion structure is further enhanced by the Hop2–Mnd complex.51 Spermatocytes or oocytes with unrepaired DSBs are expected to be eliminated due to apoptosis or undergo induced senescence. DMC1−/− mice ovaries are devoid of follicles, while depletion of Chk2 can rescue the phenotype by preventing Chk2-dependent Trp53 (p53 in humans) activation and subsequent apoptosis.46 In humans, meiotic DSB repair is furthermore facilitated by the MSH4–MSH5 heterodimer, which specifically associates with Holliday junctions, thereby stabilising the DSB intermediates.52 MSH4/5 proteins are members of the MutS homologues which are mainly implicated in mismatch repair (MMR). While MSH2, 3 and 6 are implicated in mitotic MMR, MSH4/5 are specifically active during meiosis. Interestingly, MSH5 is also expressed in granulosa cells.53 Mutations in both MSH4 and MSH5 have been detected in POI families.53 54

DNA repair-deficient mice often result in early lethality, as has been demonstrated for Rad51, Rad2B, Brca1 and Brca2 knockout models.55 Human mutations in DSB repair genes including ATM, ATR, CHEK2, RAD51 and BRCA1/2 are associated with morbid phenotypes including cancer predispositions, and to date, no clear link has been demonstrated between hypomorphic variants in these genes and an infertility phenotype. It is not clear at present whether they warrant inclusion in an infertility gene panel.

The specific case of BRCA1 and BRCA2 deserves further mention. Both proteins are involved in DSB repair and resolution of HR, and women carrying inactivating mutations are at elevated risk of cancer. A recent meta-study of carriers of BRCA1/2 variants did not reveal significant subfertility compared with a
normal control population. However, BRCA2−/− mice show a significant reduction in germline cells. Spermatocytes do not progress further than early prophase I, while oocytes have been shown to progress through prophase, although with the presence of nuclear abnormalities. Likewise, BRCA1−/− mice are subfertile, characterised by an increase in oocyte apoptosis after hormonal stimulation and smaller litter sizes. Notwithstanding these observations, the association of BRCA variation with cancer susceptibility mandates caution in including these genes in a fertility gene panel.

Meiosis: cohesin is key
On completion of HR, MI is initiated. To keep the sister chromatids together until separation in MII, spatiotemporal regulation of the cohesin complex is necessary. While the cohesin complex is located along the whole length of the sister chromatids during synopsis and HR, cohesin is depleted from the arms of sister chromatids after MI but from centromeres only in MII (figure 1). Protection of centromeric cohesin prevents premature separation of the sister chromatids at MI, which could result from the mechanical pull of the kinetochores. Failure of maintaining centromeric cohesin integrity could potentially lead to aneuploidy. In humans, the cohesin complex consists of Smc1, Smc3, Rec8 and a STAG1-3/SCC3 subunit. After HR, phosphorylation of cohesin subunits (in particular Rec8) along the length of the sister chromatids permits separase cleavage of Rec8, breakdown of the cohesin complex and separation of chromatid arms. At the centromeres, cohesin association with the shugoshin–PP2A phosphatase complex blocks phosphorylation and prevents premature separase-induced cleavage. When cells enter MII, the shugoshin–PP2A complex is antagonised by the SET protein, allowing Rec8 cleavage by separase and separation of the sister chromatids.

Meiotic segregation errors (leading to aneuploidy) increase in frequency with age, because of the incremental depletion of cohesin and Sgo2. Both male and female mice lacking Sgo2 are infertile, but in humans, SGO2 mutation has been reported only once to date. In mice, Sgo2 is furthermore stabilised by Meikin and consequentially, oocytes of Meikin−/− females display a disrupted anaphase II due to premature separation of the sister chromatids. Furthermore, human homozygous mutations in STAG3 are associated with POI. This has been mimicked in Stag3−/− mice where further investigation showed a meiotic arrest at prophase I, leading to oocyte depletion. Moreover, mice that have a knockout for Rec8, the phosphoprotein acting as a switch for separase degradation, are born in a submendelian frequency and are sterile. However, since cohesin subunits are essential for both mitosis and meiosis, mutations in these result in congenital morbidities rather than reproductive disorders; for example, SMC1A mutations cause Cornelia de Lange syndrome, an X-linked dominant disorder characterised by growth retardation, developmental delay and often microcephaly. It remains possible that hypomorphic variants in cohesin complex components and regulators may produce reproductive effects, warranting their inclusion in a diagnostic gene panel for fertility.

Failure of completing MI or MII: meiotic arrest
The impossibility of an oocyte to complete MI or MII will, in case the oocyte pool is not fully cleared in the ovaries, likely result in fertilisation failure even when intracytoplasmic sperm injection (ICSI) is applied, and this can, in theory, be caused by mutations in any of the genes described above. However, during recent years, multiple novel genes have been described as being essential for meiotic progression. Although most work has been performed in mice and Xenopus, it can be expected that similar effects can be seen in humans in the homologous genes. Mutations in PATL2 (shown in humans, mice and Xenopus), Lfng (shown in mice), Prkar2b (shown in mice), Cks1, Cks2, Mos (shown in Xenopus and mice) and Smc1b all have been shown to lead to failure to proceed through meiosis. The processes these genes are involved in are diverse. For instance, oocytes of Cks2 null mice fail to proceed after prophase I and while the same holds true for Cks1 null mice, the Cks2 null oocytes can be rescued by microinjection of Cks1 mRNA. Both Cks1 and Cks2 bind to Cdk1 and Cdk2 (cyclin dependent kinases 1 and 2, respectively) complexes thereby modulating the cell cycle. Interestingly, in Xenopus, it has been demonstrated that the CKS1 homologue strongly enhances phosphorylation of the downstream Cdk target Myt1, by which meiosis I entry is enabled. Furthermore, entry into MI in Xenopus requires Mos activation which, in turn, phosphorylates Myt1. Mos, which is an upstream activator of the mitogen-activating protein kinase (MAPK) pathway, is also implicated in maintaining the oocyte MI arrest (shown in mice and in Xenopus) by indirectly phosphorylating EM12, an inhibitor of the anaphase promoting complex. A complementary mechanism by which MI is arrested prior to the oestrous cycle is through cyclic adenosine monophosphate (cAMP)-mediated phosphorylation of Pka(cAMP-dependent protein kinase), which activates the kinase Wec2 (or Wec1b) which, in turn, will phosphorylate Cdk1, allowing the maintenance of prophase arrest. Intriguingly, when the oocyte has progressed to MII, Wec2 is also necessary for final MII exit by phosphorylation of its target Cdc2. In mice oocytes, inhibition of Wec2 results in failure of pronucleus formation and consequently to the impossibility of fertilisation. Likewise, in humans, it has recently been shown that homozygous WEE2 mutations result in oocyte fertilisation failure. Injection of WEE2 mRNA could compensate for the mutations and effectively resulted in fertilisation.

In contrast to cell cycle modulation, the Lfng protein is a regulator of Notch signalling by post-translationally modifying the N-acetylglucosamine content of the Notch receptor, resulting in alteration of its ligand binding capacity. While Lfng−/− mice are not born at Mendelian ratios, the surviving female mice are subfertile and are characterised by significantly reduced in vitro fertilisation rate as the consequence of failure to proceed to meiotic metaphase II. Interestingly, chemical inhibition of the Notch pathway in isolated mouse ovaries results in a marked downregulation of Lhx8, Figla, Sohlh2 and Nobox mRNA expression. In humans, mutations in LHx8, FIGLA, SOHLH2 and NOBOX have been demonstrated to lead to POI, thus providing a link between Notch signalling, meiotic arrest and POI. Furthermore, besides the Notch pathway, cAMP-dependent protein kinase A (PKA) signalling is crucial as well in meiotic progression. For instance, during oocyte maturation, the PKA regulator, PRKAR2b, is highly upregulated during metaphase I and RNAi-mediated PRKAR2b depletion results in failure of MI progression.

The PATL2 gene has recently been demonstrated as another essential factor for MI progression. Biallelic PATL2 mutations in women resulting in complete loss of the protein display germinal vesicle arrest, while oocytes of compound heterozygous patients with less severe mutations effectively make it through MI. However, fertilisation rates are poor, and the small number of embryos that are obtained fail in early development. Relatively little is currently known about the function of PATL2. RNAseq experiments in PATL2−/− murine oocytes...
have revealed a crucial role in the transcriptional regulation of oocyte maturation genes both in the germinal vesicle and during MII. One of the transcripts that is markedly downregulated in Patl2 mutated mouse oocytes is Cdc25a, which has also been shown to be crucial for meiotic progression. In line with this finding, translational regulation during oocyte maturation has been shown to be under control by the CPEB1 and DAZL proteins, which are responsible for ribosome loading onto oocyte-specific mRNAs. Additional transcriptional control in oocyte development has been observed for the FIGLA gene. Female Figla null mice display overexpression of testis-specific genes in their ovaries. Correspondingly, FIGLA mutations have been described in women with POI. In mice, transcriptional modulation of oocyte-specific genes, including Dazl, Figla and Nobox, is under control by the master regulator Taflb, which associates with their respective proximal promoter sequence. Consequently, mice deficient for Taflb have oocytes displaying failure of prophase I progression going together with failure in meiotic completion.98

Paracrine regulation of female meiosis

In mammalian oocytes, meiosis is arrested at the diplotene stage until the time of ovulation. Only by an increase of preovulatory levels of luteinising hormone (LH) can meiotic resumption proceed. LH acts on the outer granulosa cells and initiates a signalling cascade that has to reach the oocyte, which is separated from the outer surface of the follicle by more than 10 cell layers. The LH signal transmission and subsequent control of meiotic progression is based on cGMP diffusion through these different layers. High levels of cGMP in the oocyte result in a meiotic arrest. However, the genes Npr2 and Nppc, which are responsible for cGMP production, are only expressed in the granulosa cells, and thus, diffusion is necessary in order to obtain high cGMP levels in the oocytes. In the oocyte, cGMP inhibits phosphodiesterase 3a activity, suppressing cAMP hydrolysis, leading to a subsequent activation of PKA, which modulates the cell cycle. The dependence of the meiotic arrest on the presence of cGMP has been demonstrated in Npr2 null mice, which are infertile due to premature meiotic resumption. The importance of diffusion has, however, been evidenced in connexin 37-deficient female mice, which are infertile due to an inhibition of meiotic completion.

Connexin proteins assemble into gap junctions that are widely expressed in different cell types. In follicular tissue, connexin 37 is responsible for diffusion at the oocyte-granulosa boundary, while connexin 43-based gap junctions form the connection between the granulosa cells. Interestingly, tissue-specific overexpression of connexin 43 in connexin 37-deficient mice can restore oocyte maturation resulting in fertile female mice. Currently, two modes of action have been described that contribute to the control of the meiotic arrest under the influence of LH. Murine follicles exposed to LH show a significant decrease in cell cycle control to transcriptionally initiating and fine-tuning oogenesis. This varied repertoire in functionality strongly suggests that still more genes are awaiting to be uncovered as essential for meiotic progression. A further possible implication could be that in certain patients, a multi-genic origin can be causal for their phenotype.

Demonstrated that LH results in a significantly reduced permeability of the connexin 43 gap junctions in a MAPK-dependent way. As such, cGMP produced in the granulosa cells diffuses less efficiently to the oocyte, allowing the meiotic process to proceed.

While signalling from the granulosa cells towards the oocyte is crucial for follicular development, paracrine effects in the opposite directions play a key role as well. Oocyte expression of the Transforming Growth Factor beta (TGFb) family member proteins Gdf9 and BMP15 is essential for granulosa cell development. Binding of both proteins to the BMPRI and II receptor which are expressed on the granulosa and cumulus cells occurs from early folliculogenesis and both proteins have been shown to interact with each other, forming the heterodimer cumulin, an activator of cumulus cells that is more potent than BMP15 or GDF9 alone. Gdf9-deficient mice are only able to form primary one-layer follicles. Interestingly, Gdf9 null oocytes grow faster and larger than controls despite incomplete follicle formation but nevertheless show abnormalities including the absence of cortical granules and aberrant clustering of organelles around the germinal vesicle. Regulation of GDF9 expression is under control of the transcription factor NOBOX, and mutations in both GDF9 and NOBOX have been shown to lead to POI in humans. Furthermore, NOBOX has been shown to interact with the FOXL2 transcription factor, in which mutations of the corresponding gene result in the blepharophimosis- ptosis-epicanthus inversus syndrome, which is associated with POI as well. Additionally, mutations in BMP15 have been shown to lead to POI, suggesting that a disturbed BMP15–GDF9 interaction is contributive to the phenotype. Furthermore, regulation of BMP15 expression has recently been found to be influenced by basonuclein 1 (BNC1) expression. BNC1 mutations have been found in POI patients and resulted in reduced BMP15 expression in combination with meiotic defects in a mouse model.

MATERNAL-EFFECT FACTORS

The term ‘maternal-effect factor’ refers to maternally encoded gene products, typically expressed in her oocytes, defects that do not affect her health but compromise the development of her offspring. The majority of maternal-effect genes have been studied using mouse models, but similar mutations are now being detected in humans, in rare, clinically driven genome-wide analyses. However, their prevalence and impact are not known in the wider landscape of clinical reproductive medicine.

Some maternal-effect mutations directly affect the genome of the oocyte, and specifically the chromosome complement it delivers to the offspring. For example, a specific tubulin isoform, encoded by TUBB8, is required for the oocyte meiotic spindle, and maternal-effect mutations in TUBB8 can cause critical chromosomal defects affecting both oocytes and, remarkably, very early development of fertilised embryos. The majority of maternal-effect mutations affect proteins or mRNA deposited in the oocyte that are required for postfertilisation development. On fertilisation, the sperm genome enters the oocyte, and this triggers the completion of oocyte meiosis. The zygote then restructures and activates its genome through a coordinated sequence of functions, both epigenetically (changing the organisation of the zygote genome, and in particular the methylation of genomic DNA) and transcriptionally (potentiating expression of zygotic genes) (figure 2).
Gametes

Figure 2  Overview of the general methylation and transcriptional status of the oocyte, zygote and further developmental stages. From fertilisation on, the paternal DNA is actively demethylated. Demethylation of the maternal DNA occurs more passively, being not replaced during initial cell divisions. From the blastocyst stage on, expression of DNMT1 increases, which goes together with an increase of methylation of the embryonic DNA. Transcripts originating from the oocyte are very stable and constitute most of the mRNA during initial stages. However, from the 4–8 cell stage on, embryonic transcripts take over. SC, synaptonemal complex.

Epigenetic

The DNA methylation of oocyte and sperm are highly divergent, reflecting their highly differentiated state and gene expression patterns, but these patterns are essentially harmonised by the time of blastulation (figure 2). In the one-cell zygote, the paternal genome is rapidly and actively demethylated and appears to be predominantly passive, by reduction without replacement of DNA methylation over multiple cell cycles, possibly through restricted activity of the critical DNA methyltransferase DNMT1. By the blastula stage, the DNA methylation of the two genomes is broadly equivalent and low, with two exceptions. First, constitutive heterochromatin and repetitive DNA are highly methylated and transcriptionally repressed after a brief zygotic window of transcription. Second, a small number of sequences elude both DNA demethylation and remethylation, and thus retain the methylation state of their gamete of origin, in a phenomenon known as genomic imprinting.

Transcriptional

The maturing oocyte accumulates significant stocks of RNA and proteins, but the mature oocyte silences transcription and remains transcriptionally dormant until full zygotic genome activation (ZGA) at two-cell stage (2C) in mice, and the eight-cell stage in humans. mRNA is very stable in the growing oocyte (with an average half-life of 10–14 days). On meiotic maturation, the average mRNA half-life returns to the normal level, of minutes or hours, and the mRNA content of the oocyte rapidly drops. The progressive destabilisation of maternal mRNA, by removal of 5’ caps and shortening of 3’ polyA tails, is believed to contribute to oocyte ‘ageing’, depriving zygotes of maternal mRNA necessary for early development and reducing their fitness.

Maternal-effect genes and the zygote genome

During the remodelling of the embryonic genome, maternal-effect factors are essential, including epigenetic factors directly required for remodelling the genome and auxiliary factors that organise, stabilise and coordinate the use of maternally-provided RNA and protein until ZGA.

Epigenetic factors in the oocyte are also universally required in somatic cells, and thus highly penetrant mutations are incompatible with life; therefore, maternal-effect mutations are not readily found in human populations, and their effects have been explored in mouse models. For example, Trim28 forms a scaffold, linking DNA-binding zinc-finger proteins with DNA demethylases and chromatin modifiers. Ablation of oocyte Trim28 expression caused complete lethality: the majority of embryos failed around blastulation, and fetuses surviving beyond this time showed gross anatomical abnormalities. Interestingly, maternal null fetuses showed variably altered expression and DNA methylation of imprinted genes, suggesting that the lack of Trim28 in the first cell cycles exposed their differentially methylated regions to demethylation, which was not restored during later development. Remarkably, in both mice and humans, TRIM28 haploinsufficiency (in either maternal or paternal inheritance) predisposes to perturbed imprinted gene expression, particularly in adipose tissue, and resultant obesity. It remains to be determined whether more severe hypomorphism for TRIM28 is associated with reproductive compromise.
DNMT1, which methylates hemimethylated DNA, has both somatic and oocyte-specific isoforms. In mice, absence of maternally expressed Dnmt1 caused almost complete lethality of offspring, around midgestation, with a range of phenotypic abnormalities and DNA methylation defects, again including imprinted genes.\textsuperscript{123} \textsuperscript{124} \textsuperscript{136} Maternal haploinsufficiency for Dnmt1 has also been shown to compromise offspring outcomes and DNA methylation, though only in presence of another environmental challenge, assisted reproductive technology,\textsuperscript{157} but to date, human mutations have not been reported.

Another critical epigenetic factor is the zinc-finger DNA binding protein Zfp57. In mouse models, Zfp57 binds to a hexamer motif in hemimethylated DNA, which recruits Trim28 and thereby Dnmt1 to facilitate maintenance of DNA methylation.\textsuperscript{138} \textsuperscript{139} Combined maternal and zygotic knockout of Zfp57 in mouse results in loss of imprinted DNA methylation and midgestation lethality.\textsuperscript{140} Human Zfp57 is not a maternal-effect gene: it is expressed in the embryo, and somatic mutation carriers show imprinting disturbance and a congenital imprinting disorder, whereas maternal mutation carriers do not.\textsuperscript{141} Maternally provided Dppa3 (also known as Pgcl or Stella) is essential for protection of methylation in the early murine embryo,\textsuperscript{142} but currently, its human homologue is not associated with any reproductive phenotype.

\textbf{Maternal-effect genes and developmental competence}

Imprinting disturbance is a recurring theme in the second class of maternal-effect mutations: those whose role may not be directly genomic but possibly epigenomic or organisational. The archetype of these is mutation in \textit{NLRP7}.

Human NLRP7 has no murine homologue. It was identified as a maternal-effect gene through mutations in mothers causing a severe adverse reproductive outcome, complete hydatidiform mole. However, heterozygous maternal mutations have been identified in the mothers of adverse reproductive outcomes, or offspring with altered DNA methylation.\textsuperscript{143} \textsuperscript{144} Molar pregnancies do not produce liveborn offspring but disorganised tissue resembling extraembryonic structures. The majority are sporadic, monospermic pregnancies with no maternal contribution, but women with homozygous NLRP7 inactivation, through mutation or gene deletion, show almost complete penetrance of molar pregnancy.\textsuperscript{145} \textsuperscript{146} NLRP7-associated moles have a normal biparental chromosome complement but complete loss of DNA methylation on maternally methylated imprints.\textsuperscript{149} Molar pregnancies also result from maternal-effect mutations of \textit{KHDC3L1},\textsuperscript{150} whose protein product associates with NLRP7 in the oocyte.\textsuperscript{151}

\textit{NLRP7} is one of a gene family, several of which are tandemly located and the products of recent duplication in mammalian evolution.\textsuperscript{152} Several NLRPs are involved in humoral immunity,\textsuperscript{153} while others are expressed almost exclusively and abundantly in the oocyte. Nlrp5 (also known as Mater) was one of the first maternal-effect genes identified.\textsuperscript{154} Along with four other factors, Pad6, Khdc3 (also known as Filia), Moep and Tle6, Nlrp5 is among the most highly expressed proteins in the oocyte.\textsuperscript{155} \textsuperscript{156} These proteins form a very high molecular weight complex, identified in some reports as the subcortical maternal complex\textsuperscript{40} and others as cytoplasmic lattices (CPLs).\textsuperscript{157} Maternal ablation of murine Nlrp5 causes arrest at the 2C stage.\textsuperscript{158} In these maternal-null zygotes, CPLs are not formed, and the majority of oocytes do not attain the ‘surrounded-nucleolus’ confirmation associated with early viability.\textsuperscript{159} Khdc3l1 and Moep both have RNA-binding domains and RNA-binding activity in vitro.\textsuperscript{158} Maternal-null Khdc3l1 mice have 50% fertility, with abnormalities of spindle assembly and chromosome alignment that cause delayed mitosis and gross aneuploidy.\textsuperscript{159} Maternal null Moep−/− embryos show delayed and asymmetric cell division resulting in arrest at 2C–4C. Pad6 interacts with the mitotic spindle and actin cytoskeleton of the oocyte, as well as with ribosomes; maternal ablation leads to disappearance of CPL, altered localisation of ribosomal components, reduced protein translation, reduced PolII transcription and developmental arrest at 2C–4C.\textsuperscript{160} Tle6 is a phosphorylation target of PKA in oocyte maturation,\textsuperscript{161} but its function is not known. In humans, maternal-effect mutations have to date been identified in all these factors.\textsuperscript{162} Inactivating mutations of PAD16 and TLE6 were found in mothers undergoing IVF for infertility, whose embryos arrested at 2C.\textsuperscript{163} \textsuperscript{164} \textit{KHCDC3L1} mutations have been shown to cause familial hydatidiform mole. NLRP5 variants caused a range of developmental outcomes, including infertility, molar pregnancy, miscarriage and liveborn children affected by diverse imprinting disorders, and atypical imprinting disorders were also described in offspring of a mother with NLRP2 mutations.\textsuperscript{165} Other maternal-effect genes identified through murine studies but without currently identified human effects include \textit{Hsf1}, \textit{Npm2}\textsuperscript{166} and \textit{Zip3}.\textsuperscript{168} Detailed characterisation of maternal-effect mutations in appropriate model systems is needed to reveal their mechanisms. It is plausible that complete or near-complete loss of function would cause zygote arrest before ZGA and apparent infertility. It is furthermore very likely that environmental, medical, genetic and epigenetic problems all contribute to infertility and reproductive wastage, but their relative contributions are unclear.

\textbf{PHENOTYPE SELECTION}

Errors in MI could lead to an outcome of POI: the impossibility to proceed to MI might trigger an apoptotic effect in the immature oocytes, whereas failure to stop the meiotic cycle after completion of MI has been shown to lead to a premature depletion of the oocyte pool. Mutations in genes implicated in the formation of DSBs, chromosome synopsis, HR and separation of homologous chromosomes, which are the main processes occurring during MI, could therefore potentially be involved in patients with a POI phenotype. Alterations in genes regulating maternal-effect processes are expected to result in embryos that halt further development at a certain (early) stage. Moreover, and especially in an IVF setting, aberrations in maternal effects might lead to an increase in low-quality embryos as well.

Additionally, errors in the mechanisms spanning the timeframe between ovulation and completion of MI postfertilisation could lead to a reduced fertilisation rate or failure of the embryo to further develop. It has to be noted however that diminished fertilisation can have other causes as well, ranging from paternal effects to defects in the acrosomal reaction, processes that are not included in this review.

In an ART/IVF clinical setting, defects in meiosis or maternal-effect genes are expected to give rise to a specific phenotype. We therefore propose to initiate gene panel testing in patients with the following characteristics in the IVF clinic: (1) oocyte maturation rate lower than 20% in the absence of endocrinological or technical issues in normal responders, (2) fertilisation rate lower than 10% in the absence of overt male factor and (3) embryo development rate lower than 10% in the absence of lab issues. However, prior to setting these criteria, severe parental phenotypes (including immune problems) and high levels of sperm damage should be excluded. Sperm parameters including concentration, motility and morphology have been associated.

\textbf{Gametes}

\textbf{Gheldof A, et al. J Med Genet 2019;0:1–12. doi:10.1136/jmedgenet-2018-105513}
CONCLUDING REMARKS

The last decade has shown a significant increase in the genetic and molecular characterisation of fertility-related processes and has given us a more clear insight in the cellular machinery that drives meiosis and maternal-effect processes. This research has predominantly been done in yeast and mice and has revealed a myriad of novel proteins, both species specific and evolutionary conserved, adding further to the complex regulation of these processes. Given the molecular complexity of the meiotic process and its regulation, it is to be expected that multigenic alterations or polymorphisms could lead to gradation of an infertility phenotype resulting from a deregulated meiotic process. It is however unlikely that the use of a targeted gene panel will be able to identify these subtle effects. In order to accomplish this, one would need a much more detailed description of the phenotype as well as a large enough amount of samples with similar phenotype. However, by using a meiotic gene-specific panel in combination with a highly specific phenotype that is readily identifiable by fertility centres, one can hope to further uncover the contribution of single genes and as such identify the underlying cause of infertility of a proportion of idiopathic patients. Furthermore, this would greatly improve our understanding of the meiotic/maternal-effect process and bring into view the impact certain genes have on the severity of the phenotype. More importantly in terms of clinical practice, this would aid patients in their treatment regime as well as patient families in terms of counselling.

Meiosis heavily depends on the formation and repair of double stranded breaks and mutations in genes that are implicated in this process and have been associated with cases of familial cancer. When mutations are found in any of these particular genes, the consulting physician or the fertility centre should have implemented well-considered scenarios into their counselling practice. This is, however, complicated by the fact that while for some repair genes, for instance \( BRCA1 \) and \( BRCA2 \), the connection with familial breast and ovarian cancer is clear, while for other repair genes, this is much less clear or even unknown at the moment. One approach to avoid this ethical issue is to simply omit the repair genes in the panel. Whether the benefits of this approach outweigh the disadvantages should be decided by the individual fertility centres in close collaboration with ethicists.

In this review, we have described candidate genes involved in two cellular processes, namely meiosis and maternal effects, which are eligible for playing a role in specific cases of idiopathic infertility. By using this set of genes in a diagnostic grade panel in combination with a specifically selected phenotype may improve the diagnosis for idiopathic infertility patients who fall into the selected category. We realise that our gene set is not complete from a biological point of view. However, in terms of clinical applicability, the future implementation of a limited gene panel can bring a significant benefit to the follow-up, treatment and counselling of patients. An overview of the different genes described can be found in additional online supplementary table 1.

REFERENCES

1. Esteves SC, Hamada A, Kondray V, Pitchika A, Agarwal A. What every gynecologist should know about male infertility: an update. *Arch Gynecol Obstet* 2012;286:217–29.
2. Laissue P. Aetiological coding sequence variants in non-syndromic premature ovarian failure: From genetic linkage analysis to next generation sequencing. *Mol Cell Endocrinol* 2015;411:243–57.
3. De Vos M, Devroey P, Fauser BCJM. Primary ovarian insufficiency. *The Lancet* 2010;376:911–21.
4. Lee JS, Dada R, Sabanegh E, Carpi A, Agarwal A. Role of genetics in azoospermia. *Urology* 2011;77:598–601.
5. Donker RB, Vloethings V, Groen H, Tournaye H, van Ravenswaaij-Arts CMA, Land JA. Chromosomal abnormalities in 1636 infertile men with azoospermia: the clinical consequences. *Hum Reprod* 2017;32:2574–80.
6. Colicchio G, Dai Canto M, Mignini Renzini M, Guglielmo MC, Brambilla E, Turchi D, Novara VP, Fadini R. Oocyte maturation: gamete-somatic cells interactions, meiotic resumption, cytoskeletal dynamics and cytoplasmic reorganization. *Hum Reprod Update* 2015;21:427–54.
7. Venkatesh T, Suresh PS, Tsutsumi R. New insights into the genetic basis of infertility. *Appl Clin Genet* 2014;7:235–43.
8. Rossetti R, Ferrari I, Bonomi M, Persani L. Genetics of primary ovarian insufficiency. *Clin Genet* 2017;91:183–98.
9. Harper JC, Attoomkai M, Bony P, Cornel MC, de Weert G, Dondorp W, Geraerts J, Gianaroli L, Ketterson K, Liebaers I, Lundin K, Merete H, Morris M, Pennings G, Sermon K, Spits C, Soins S, van Montfoort APA, Veiga A, Vervecken JR, Villette S, Mackel M, on behalf of the European Society of Human Reproduction and Embryology and European Society of Human Genetics. Recent developments in genetics and medically-assisted reproduction: from research to clinical application touched upon. *Hum Reprod Open* 2017;2017.
10. Geisinger A, Benavente R. Mutations in genes coding for synaptoplasm complex proteins and their impact on human fertility. *Cytogenet Genome Res* 2016;150:77–85.
11. Handel MA, Schimenti JC. Genetics of mammalian meiosis: regulation, dynamics and impact on fertility. *Nat Rev Genet* 2010;11:124–36.
12. Sytjänen JL, Pellegrini L, Davies OR. A molecular model for the role of SYCP3 in meiotic chromosome organisation. *Elife* 2014;3:03963.
13. Miyamoto T, Hasukui S, Yoge V, Maduro MR, Ishikawa M, Westphal H, Lamb DJ. Azoospermia in patients heterozygous for a mutation in SYCP3. *Lancet* 2013;382:1714–9.
14. Bolor H, Mori T, Nishiyama S, Ito Y, Hosoba E, Inagaki H, Kogo H, Ohye T, Tsutsumi M, Kato T, Tong M, Nishiwa M, Pryor-Koishi K, Kitaoka E, Sawada T, Nishiyama Y, Udagawa Y, Kurahashi H. Mutations of the SYCP3 gene in women with recurrent pregnancy loss. *Am J Hum Genet* 2009;84:14–20.
15. De La Fuente YJ. Cell Biol 2006;173:497–507.
16. Zhou J, Stein P, Leu NA, Chmatalá L, Xue J, Ma J, Huang X, Lampson MA, Schultz RM, Wang PJ. Accelerated reproductive aging in females lacking a novel centromere protein SYCP2L. *Hum Mol Genet* 2015;24:6505–14.  
17. Maor-Sajee E, Cinnamon Y, Yaacov B, Shaag A, Goldsmith H, Zevi S, Laifer N, Richter C, Frenkiel A. Deletional mutation in SYCE1 is associated with non-obstructive azoospermia. *J Assist Reprod Genet* 2015;32:887–91.
18. Bolcan-Flais E, Hall E, Speed R, Taggart M, Grey C, de Massy B, Benavente R, Cooke HJ. Mutation of the mouse Syce1 gene disrupts synapsis and suggests a link between synaptoplast complex structural components and DNA repair. *Plas Genet* 2009;5:e1000393.
the SPO11 and recombination associated with chromosome 21 nondisjunction. Chromosoma 2005;84:758–60.

Prior S, Moresco E, Robertson M, Lasko P. Homologous recombination and human health: the roles of BRCA1, BRCA2, and associated proteins. Cold Spring Harb Perspect Biol 2015;7:a016600.

Smith KR, Hanson RA, Hollingshaus MS, BRCA1 and BRCA2 mutations and female fertility. Curr Opin Obstet Gynecol 2013;25:207–13.

Sharan SK. BRCA2 deficiency in mice leads to meiotic impairment and infertility. Development 2004;131:131–42.

Titus S, Li F, Stoebezi B, Akula K, Unsell E, Jeong K, Dickler M, Robson M, Moy F, Gowsami S, Oktay K. Impairment of BRCA1-related DNA double-strand break repair leads to ovarian aging in mice and humans. Sci Transl Med 2013:5:121ra21.

Nasymyth K, Haring CH. Cohesin: its roles and mechanisms. Annu Rev Genet 2009;43:525–58.

Higgins JM, Herbert M. Nucleosome assembly proteins get SET to defeat the guardian of chromosome cohesion. PLoS Genet 2013;9:e1003829.

Chambon JP, Touati SA, Berneau S, Cladière D, Hebras C, Groene R, McDouggall A, Wassmann M. The PP2A inhibitor I2PP2A is essential for sister chromatid segregation in meiotic oocytes II. Curr Biol 2013;23:485–90.

Lister LM, Kouznetsova A, Hyslop LA, Kalles D, Pace SL, Barel JC, Nathan A, Floros V, Adellaflc C, Watanabe Y, Jessberger R, Kirkwood TB, Hölz C, Herbert M. Age-related meiotic segregation errors in mammalian oocytes are prevented by depletion of cohesin and Spo2. Curr Biol 2010;20:1511–21.

Faridi R, Rehman AU, Morrell RJ, Friedman PL, Demain L, Zahrara S, Khan AA, Tohloid D, Assiz M, Beamant G, Khan SN, Newman W, Riazuddin S, Friedman TB. Mutations of SC02 and CD141 collectively cause coincidental perlurtar syndrome. Clin Genet 2015;87:328–32.

Kim J, Ishiguro K, Namba A, Akiyoshi B, Kobayakashi S, Kagami A, Ishiguro T, Pendas AM, Takeda N, Sakakibara Y, Kitajima TS, Yano K, Sakuto T, Watanabe Y. Meikin is a conserved regulator of meiosis-I-specific kinetochore function. Nature 2015;517:466–71.

Cabaret S, Arborelo VA, Llano E, Overbeeke PA, Barbero JL, Oka K, Harrison W, Vaiman D, Ben-Neriah Z, Garcia-Tutuila E, Fellous M, Pendas AM, Veitia RA, Vilain E. Mutant cohesin in premature ovarian failure. Nat Ecol Evol 2017;1:343–93.

Xu H, Beasley MD, Warren WD, van der Horst GTJ, Mckay MJ. Absence of mouse recombination isoenzyme promotes premature ovarian failure. Dev Cell 2005;8:594–61.

Limongelli G, Russo S, Diggio MC, Masciari M, Patiño LC, Mateus H, Bolcun-Filas E, Bolcun-Filas D, Filas M, Jang JS, Jen J, Babovic-vulkanic D, Hodge JC. In-frame exon deletion of SMC1A in a severely affected female with Cornelia de Lange Syndrome. Am J Med Genet A 2012;158:A193–8.
Gametes

69 Spruck CH, de Miguel MP, Smith AP, Ryan A, Stein P, Schultz RM, Lincoln AJ, Donovan PJ, Reid SJ. Requirement of Cks1 for the first metaphase/anaphase transition of mammalian meiosis. Science 2003;300:647–50.

70 Libby BJ, De La Fuente R, O’Brien MJ, Wigglesworth K, Cobb J, Inselman A, Eaker S, Handel MA, Eppig JJ, Schimenti JC. The mouse meiotic mutation mei disrupts chromosome synapsis with sexually dimorphic consequences for meiotic progression. Dev Biol 2002;242:174–87.

71 Arai K, Naito K, Haraguchi S, Suzuki R, Yokoyama M, Inoue M, Aizawa S, Toyoda Y, Sato E. Meiotic abnormalities of c-mos knockout mouse oocytes: activation after first meiosis or entrance into third meiotic metaphase. Biof Res 1996;55:1315–24.

72 Hahn KL, Johnson J, Beres BJ, Howard S, Wilson-Rawls J. Luteinizing fringe null female mice are fertile due to defects in meiotic maturaion. Development 2005;132:187–193.

73 Edelmann W, Cohen PE, Kane M, Lau K, Morrison B, Bennett S, Umar A, Kunkel T, Cattrogetti G, Chagnard R, Pollard JW, Kolodner RD, Kucherlapati R. Meiotic pachytene arrest in MLH1-deficient mice. Cell 1996;85:1125–34.

74 Martinsson-Atléns H, Liberal V, Grünfelder B, Chaves S, Spruck CH, Reid SJ. Cyclin-dependent kinase-associated proteins Cks1 and Cks2 are essential during early embryogenesis and for cell cycle progression in somatic cells. Mol Cell Biol 2008;28:5696–709.

75 Egan GA, Solomon MJ. Cyclin-stimulated binding of Cks proteins to cyclin-dependent kinases. Mol Cell Biol 1998;18:3659–67.

76 Patra D, Wang SX, Kumagai A, Dunphy WG. The xenopus Suc1/Cks proteins promote the phosphorylation of G, M regulators. J Biol Chem 1999;274:36839–42.

77 Ruos EL, Vilar M, Needleman N. A two-step inactivation mechanism of Myt1 ensures CDC15B2 activation and meiosis I entry. Curr Biol 2010;20:717–23.

78 Tang W, Wu JQ, Guo Y, Hansen DV, Perry JA, Free C, Nett L, Jackson PK, Kombutha S. Cdc2 and Mus regulate Emi2 stability to promote the meiosis-I transition. Mol Cell 2008;30:3563–43.

79 Miyagi K, Kanemoto Y, Baba T. Possible involvement of mitogen- and stress-activated protein kinase in the meiosis I progression of mouse oocytes. Hum Reprod 2018;45:2009–20.

80 Choi Y, Mu J, Li Q, Jin L, He L, Huan Y, Xia G. Knockdown of PRKAR2B results in the failure of oocyte maturation. Cell Death Dis 2017;8:e2662.

81 McNatty KP, Juengel JL, Reader KL, Sun S, Myllämmä S, Lawrence SB, Western A, Meersahafi MB, Motterhead DG, Gnome NF, Ritos O, Latifinen M. Bone morphogenetic protein 15 is critical for granulosa cell function in humans. Reproduction 2005;129:481–7.

82 Otsuka F, McIntosh KJ, Shimasaka S. Integral role of GDF-9 and BMP-15 in ovarian function. Mol Reprod Dev 2011;8:79–91.

83 Motterhead DG, Sugimura A, Al-Musalwi SI, Li J, Richard D, White MA, Martin GTA, Atripp RP, Ritter L, Shi J, Mueller TD, Hanson CA, Gilchrist RB, Cumulín, An Oocyte-secreted Heterodimer of the Transforming Growth Factor-β Family, Is a Potent Activator of Granulosa Cells and Improves Oocyte Quality. J Biol Chem 2015;290:24007–20.

84 Dong J, Albertini DF, Nishimori K, Kumar TR, Lu N, Matzuk MM. Growth differentiation factor-9 is required during early ovarian folliculogenesis. Nature 1996;383:531–5.

85 Carabatosi MJ, Elkin I, Matzuk MM, Albertini DF. Characterization of oocyte and follicle development in growth factor differentiation-9-deficient mice. Dev Biol 1998;203:374–83.

86 Li L, Wang B, Wang Z, Chen B, Luo M, Wang J, Xao C, Yee K, Xao Y, Bo X. Invovlement of granulosa cell function in ruminants. Repродuction 2005;129:481–7.

87 Li L, Wang B, Chen M, Wang J, Xao C, Yee K. A homologous NOBOX truncating variant causes defective transcriptional activation and leads to primary ovarian insufficiency. Hum Reprod Off J 2013;27:2448–55.

88 Antiofu LC, Walti JR, Mueller TD, Johnson KE, Stocker W, Richani D, Agapou D, Gilchrist RB, Laissle P, Hanson CA, BMP15 Mutations associated with primary ovarian insufficiency reduce expression activity, or synergies with GDF9. J Clin Endocrinol Metab 2017;102:1009–19.

89 Boulilly J, Roucher-Boulez F, Gompe A, Bry-Gauliard H, Azibi K, Beldjord C, Dode C, Bouilang J, Mantel AG, Delerme B, Young J, Einart N. Novel NOBOX mutations identified in a large cohort of women with primary ovarian insufficiency decrease KIT-L expression. J Clin Endocrinol Metab 2015;99:1004–11.

90 Boulilly J, Bachelot A, Bourin T, Einart N. Novel NOBOX loss-of-function mutations account for 6.2% of cases in a large primary ovarian insufficiency cohort. Hum Mutat 2011;32:1108–13.

91 França MM, Funari MFA, Nishi MY, Nacirano AM, Domenico S, Cezere EM, Leraia AM, Mendonça BB. Identification of the first homologous 1p deletion in GFP5 gene leading to primary ovarian insufficiency by using targeted massively parallel sequencing. Clin Genet 2018;93:408–11.

92 Bloujil J, Véra-Byard F, Gompe A, Bry-Gauliard H, Azibi K, Beldjord C, Dode C, Bouilang J, Mantel AG, Delerme B, Young J, Einart N. Novel NOBOX mutations identified in a large cohort of women with primary ovarian insufficiency decrease KIT-L expression. J Clin Endocrinol Metab 2015;99:1004–11.

93 Li L, Wang B, Wang Z, Chen B, Luo M, Wang J, Xao C, Yee K, Xao Y, Bo X. Invovlement of granulosa cell function in ruminants. Reproduction 2005;129:481–7.

94 Fung L, van den Berg MM, van Maastricht MC, van Welle G, Meijer M. Genetics of early miscarriage. Biochim Biophys Acta 2012;182:1951–9.

95 Peng F, Sang Q, Xuan Z, Yan X, Zan Z, Shi J, Tan G, Luchnauk A, Fukuda Y, Yi B, Yu M, Chen J, Xu J, Guo L, Qu L, Wang R, Sun Z, Liu S, M I, Wang H, Heng F, Yang S, Shao R, Chai L, Li Q, Xiong Q, Zang N, Nagales E, Jin J, He L, Gupta ML, Cowan NJ, Wang L. Mutations in TUBB8 and Human Oocyte Meiotic Arrest. N Engl J Med 2016;374:223–32.

96 Feng R, Yan Z, Li B, Yu M, Sang Q, Tan G, Yu X, Chen B, Qu R, Sun Z, Sun X, Liu H, He L, Kang Y, Cowan NL. Mutations in TUBB8 contribute a multiplicity of phenotypes in human oocytes and early embryos. J Clin Endocrinol Metab 2016;102:1108–13.

97 Stewart KR, Veloselova L, Kelsey G. Establishment and functions of DNA methylation in the germline. Epigenomics 2016;8:339–413.

98 Stewart KR, Veloselova L, Kim J, Huang J, Saadell H, Tomizawa S, Smallwood SA, Chen T, Kelsey G. Dynamic changes in histone modifications precede de novo DNA methylation in oocytes. Genes Dev 2015;29:1204–40.

99 Smallwood SA, Tomizawa S, Krueger F, Roff N, Carli N, Segonds-Pichon A, Sato S, Hata K, Andrews SR, Kelsey G. Dynamic changes in histone modifications precede de novo DNA methylation in oocytes. Genes Dev 2015;29:1204–40.

100 Gheldof A, et al. J Med Genet 2019;56:1–12. doi:10.1136/jmedgenet-2018-105513

101 J Med Genet 2019;56:1–12. doi:10.1136/jmedgenet-2018-105513 on 6 February 2019. Downloaded from
NLRP7 in the spectrum of reproductive wastage: rare non-synonymous variants confer genetic susceptibility to recurrent reproductive wastage. J Med Genet 2011;48:540–8.

144 Caliebe A, Richter J, Ammerpohl O, Kanber D, Beygo J, Bens S, Haake J, Juttner E, Kom B, Mackay DJ, Martin-Suerojo J, Nagel I, Seiblitz M, Seidelmann L, Vater I, von Kaisenberg B, Temple J, Tronick B, Siebri R. A familial disorder of altered DNA-methylation. J Med Genet 2014;51:407–12.

145 Soellner L, Beggeman M, Deganhard F, Geipel A, Eggemann T, Mangold E. Maternal heterozygous NLRP7 variant results in recurrent reproductive failure and impairment in fertilization disturbances in the offspring. Eur J Hum Genet 2017;25:924–9.

146 Wang CM, Dixon PH, Descarreaux S, Hodges MD, Seiblitz M, Uzayli S, Fallahian M, Sensi A, Ashirafi F, Resipka V, Zhao J, Xiang Y, Savage PM, Seidll M, Fisher R. Identification of 13 novel NLRP7 mutations in 20 families with recurrent hydatidiform mole: missense mutations cluster in the leucine-rich region. J Med Genet 2009;46:569–75.

147 Akoury E, Gupta N, Bagga R, Brown S, Déry C, Kabra M, Sinrisavan R, Slim R. Live births in women with recurrent hydatidiform mole and two NLRP7 mutations. Reprod Biomed Online 2015;31:120–4.

148 Reddy R, Nguyen NM, Sarabag R, Rezeai M, Rivas MC, Kavusoglu A, Berkal H, Elishafo A, Abdalla E, Nunup K, Dreyfus H, Philippe M, Hadipour Z, Durmaz EA, Eaton EE, Schubert U, Ulker V, Hadipour F, Ahmadpour F, Touitou I, Faradai M, Slim R. The genomic architecture of NLRP7 is Ali rich and predisposes to disease-associated large deletions. Eur J Hum Genet 2016;24:1445–52.

149 Sanchez-Delgado M, Martin-Trujillo A, Tayama C, Vidal E, Esteller M, Iglesias-Platas I, Deo N, Barney O, Madekan E, Hata K, Nakabayashi K, Fisher R, Monk D. Absence of maternal methylation in biparental hydatidiform mole from women with nlrp7 maternal-effect mutations reveals widespread placenta-specific imprinting. PLoS Genet 2015;11:e1005644.

150 Parry DA, Logan CV, Hayward BE, Shires M, Landolsi H, Ding K, Carr J, Rittore C, Touitou I, Philibert L, Fisher RA, Fallahian M, Huntriss JD, Picton HM, Malik S, Taylor GR, Johnson CA, Bonthont DT, Sheridan EG. Mutations causing familial biparental hydatidiform mole implicate ecf0r212 as a possible regulator of genomic imprinted in the human. J Med Genet 2011;48:451–5.

151 Akoury E, Zhang L, Ao A, Slim R. NLRP7 and HKDC3, the two maternal-effect proteins responsible for recurrent hydatidiform mole, co-localize to the oocyte cytoskeleton. Hum Reprod 2015;30:159–69.

152 Tian X, Pascall G, Montep E. Evolution and functional divergence of NLRP genes in mammalian reproductive systems. BMC Evol Biol 2009;9:202.

153 Radian AD, de Almeida L, Dorfleutner A, Stehlik C. NLRP7 and related inflammasome activating pattern recognition receptors and their function in host defense and disease. Microbes Infect 2013;15:630–9.

154 Tong ZB, Gold I, Pfeifer KE, Dorward H, Lee E, Bundy CA, Dean J, Nelson LM, Mater A, a maternal effect gene required for early embryonic development in mice. Nat Genet 2000;26:267–8.

155 Wang S, Kou Z, Jing Z, Zhang Y, Guo X, Dong M, Wilmut I, Gao S. Proteome of mouse oocytes at different developmental stages: In. Proc Natl Acad Sci , 2010;107, 17639–44.

156 Virant-Klun I, Leicht S, Hughes C, Krijgsfeld J. Identification of maturation-specific proteins by single-cell proteomics of human oocytes. Mol Cell Proteomics 2016;15:2616–27.

157 Monti M, Zanoni M, Calligaro A, Ko MS, Matur R. Redi CA. Developmental arrest and mammal antl not-sorparated nucleous oocytes. Biol Reprod 2013;88:62.

158 Heine H, Chentzhin G, Derelin L, Mervuuki K, Vemuganti S, Fickinger CJ. Distribution of RNA binding protein MOEP19 in the oocyte cortex and early embryo indicates pre-targeting related to blastomere polarity and trophoderm formation. Dev Biol 2008;314:300–16.

159 Zheng P, Dean J. Role of Fila, a maternal effect gene, in maintaining euploidy during cleavage-stage mouse embryoogenesis. Proc Natl Acad Sci U S A 2009;106:7473–8.

160 Yurttas P, Vilela AM, Fitzherry RJ, Cohen-Gould L, Wu W, Gossen JA, Comnord RC. Role for PBD2P6 and the cytoplasmic lattices in normal storage in oocytes and translational control in the early mouse embryo. Development 2008;135:2627–36.

161 Duncan FC, Padilla-Banks E, Berndt ML, Ord TS, Jefferson WN, Moss SB, Williams CJ. Transducin-like enhancer of split-6 (TLE6) is a substrate of protein kinase A activity during mouse oocyte ooky. Biol Reprod 2014;90:63.

162 Beggeman R, Rezwan F, Beygo J, Docherty LE, Kolarova J, Schroeder C, Buiting K, Chokshakalgun K, Degenhard F, Waielk EL, Kleine S, González Fasssainer D, Dellar-Jatchwitz B, Turner CLS, Patalan M, Gwenska M, Binder G, Rich Ngc CP, Chi Dung V, Mehta SG, Baynag X, Hamilton-Shıld JP, Aljarenie A, Lokudo-Sodge I, Horton R, Siebrits R, Buitrom M, Temple J, Eggemann T, Mackay D. Maternal variants in NLRP and other maternal effect proteins are associated with multicystic imprinting disturbances in oocytes. J Med Genet 2018;55:497–504.

163 Alazami AM, Awad SM, Coskun S, Al-Hassan S, Hijazi H, Alwahab Faham AW, Poizat C, Alkuraya FS. TL NLRP7 mutations causes the earliest known human embryonic lethality. Genome Biol 2015;16:240.
Gametes

165 Meyer E, Lim D, Pasha S, Tee LI, Rahman F, Yates JR, Woods CG, Reik W, Maher ER. Germline mutation in NLRP2 (NALP2) in a familial imprinting disorder (Beckwith-Wiedemann Syndrome). *PloS Genet* 2009;5:e1000423.

166 Christians E, Davis AA, Thomas SD, Benjamin JJ. Maternal effect of Hsf1 on reproductive success. *Nature* 2000;407:693–4.

167 Bums KH, Viveiros MM, Ren Y, Wang P; DeMayo FJ, Frail DE, Eppig JJ, Matzuk MM. Roles of NPM2 in chromatin and nucleolar organization in oocytes and embryos. *Science* 2003;300:633–6.

168 Ramos SB, Stumpo DJ, Kennington EA, Phillips RS, Bock CB, Ribeiro-Neto F, Blackshear PJ. The CCCH tandem zinc-finger protein Zfp36l2 is crucial for female fertility and early embryonic development. *Development* 2004;131:4883–93.

169 Zhang J, Xue H, Qiu F, Zhong J, Su J. Testicular spermatozoon is superior to ejaculated spermatozoon for intracytoplasmic sperm injection to achieve pregnancy in infertile males with high sperm DNA damage. *Andrologia* 2018:e13175.

170 Cooper TG, Noonan E, von Eckardstein S, Auger J, Baker HW, Behre HM, Haugen TB, Kruger T, Wang C, Mbizvo MT, Vogelsong KM. World Health Organization reference values for human semen characteristics. *Hum Reprod Update* 2010;16:231–45.

171 Cissen M, Wely MV, Scholten I, Mansell S, Bruin JP, Mol BW, Braat D, Repping S, Hamer G. Measuring sperm DNA fragmentation and clinical outcomes of medically assisted reproduction: a systematic review and meta-analysis. *PloS One* 2016;11:e0165123.